Bone Marrow Mesenchymal Stem Cells, Fresh
Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into the cells of the connective tissue in vitro, such as chondrocytes (cartilage), osteoblasts (bone) and adipocytes (fat). Although little is known of the phenotypic characteristics of MSCs in vivo, MSCs in culture are defined by the expression of CD73, CD90, and CD105 and the lack of CD11b, CD19, CD34, CD45, and HLA-DR. Cultured MSCs have shown promising applications in cell-based therapeutic strategies for specific tissues and cancer research.
Bone marrow mononuclear cells (MNCs) are separated from whole bone marrow by a density gradient centrifugation protocol. MNCs are cultured for 9-14 days in a medium that promotes MSCs. After culture, adherent cells are checked for >90% expression of CD73, CD90, and CD105 and <5% expression of CD14, CD34, and CD45 by flow cytometry.
Please request for cells to be cultured in animal component free (ACF) and serum-free medium.
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
|Cell and Tissue Source||Bone Marrow|
|Product Type||Primary Cells|
|Cell Type||Mesenchymal Stem Cells|
|Donor Attributes||HIV-, HepB-, HepC-|
|Purity||≥90% CD73, CD90, and CD105 and <5% CD14, CD34, and CD45 by Flow Cytometry|
|Viability||≥85% by Flow Cytometry|
Product Information Sheet
Certificate of Analysis
Material Safety Data Sheet
Figure 1. Representative flow data of enriched MSCs from bone marrow prior to cryopreservation. MSCs have a >90% expression of CD90, CD105, and CD73.
Figure 2. Representative flow data of enriched MSCs from bone marrow prior to cryopreservation. MSCs have <5% expression of CD14, CD34, and CD45 (panel of antibodies used).